Autolus Therapeutics plc

Most Recent

Miscellaneous
T-Cell Pipeline Is a Key Growth Driver for Autolus Therapeutics
The 12-month consensus analyst recommendation for Autolus Therapeutics (AUTL) on September 25 is a “strong buy.”

By Margaret PatrickSep. 6 2019, Updated 6:16 p.m. ET

ABOUT Market Realist
About Us
Privacy Policy
Terms of Use
DMCA

CONNECT with Market Realist

© Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.

Autolus Therapeutics plc

T-Cell Pipeline Is a Key Growth Driver for Autolus Therapeutics